Hurenkamp GJ et al. |
Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930901
|
Lai KC et al. |
Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930902
|
Pilotto A et al. |
Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930903
|
Kihira K et al. |
Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930904
|
Kamada T et al. |
Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930905
|
Savarino V et al. |
OAM for cure of Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930908
|
Perri F et al. |
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421877
|
Perri F et al. |
Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421878
|
Pilotto A et al. |
Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421879
|
Tepes B et al. |
Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer? |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421880
|
Calvet X et al. |
What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421884
|
Huang J et al. |
Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:24117692
|
Molina-Infante J et al. |
Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. |
2010 |
Aliment. Pharmacol. Ther. |
pmid:20180787
|
Chacko Y and Holtmann GJ |
Helicobacter pylori eradication and weight gain: has it opened a Pandora's box? |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21679208
|
Zullo A et al. |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15948808
|
Wong BC et al. |
Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11380322
|
Meier R et al. |
Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11380323
|
Harb AH et al. |
Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:26011564
|
Miehlke S et al. |
Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16842467
|
Spinzi G et al. |
Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9146769
|
Peterson WL |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9146787
|
Veldhuyzen Van Zanten S et al. |
One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12786632
|
Wong BC et al. |
One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207516
|
Fakheri H et al. |
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207517
|
Nagahara A et al. |
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207518
|
Bardhan KD et al. |
Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632646
|
Cammarota G et al. |
Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632648
|
Gasbarrini A et al. |
Efficacy of a multistep strategy for Helicobacter pylori eradication. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632649
|
Chan FK et al. |
Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632651
|
Khurana R et al. |
Meta-analysis: Helicobacter pylori eradication treatment efficacy in children. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17305754
|
Pipkin GA et al. |
Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768524
|
Fischbach LA et al. |
Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15569109
|
Louw JA et al. |
Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768531
|
Laine L et al. |
Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768532
|
Gu Q et al. |
Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15352916
|
Tomita T et al. |
Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966543
|
Axon AT et al. |
Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042977
|
Labenz J et al. |
One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042978
|
Labenz J et al. |
Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042979
|
Kim JS et al. |
Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860410
|
Poon SK et al. |
Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860412
|
Peitz U et al. |
High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860415
|
Sheu BS et al. |
Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12197847
|
Calvet X et al. |
One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12144575
|
Di Caro S et al. |
Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876707
|
Wu JC et al. |
Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876709
|
Basset C et al. |
Helicobacter pylori infection: anything new should we know? |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15335411
|
Mason J et al. |
The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876711
|
Georgopoulos SD et al. |
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876712
|
Calvet X et al. |
A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10792124
|
Savarino V et al. |
Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:9892878
|
Spinzi GC et al. |
Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663722
|
Bazzoli F et al. |
Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663723
|
Pozzato P et al. |
Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663724
|
Goh KL et al. |
Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663838
|
Goddard AF et al. |
Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10233187
|
Kolkman JJ et al. |
Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663840
|
Pilotto A et al. |
The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10233191
|
Miyaji H et al. |
Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663841
|
Wong BC et al. |
Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11069326
|
Lionetti E et al. |
Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:17032283
|
Iijima K et al. |
Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15153171
|
Laurent J et al. |
A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11683693
|
O'Connor HJ et al. |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9570262
|
Scott BB |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9570263
|
Goodgame RW et al. |
Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11736715
|
Malfertheiner P et al. |
Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12752349
|
Gené E et al. |
Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12752350
|
Sheu BS et al. |
The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12755841
|
Canducci F et al. |
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11121911
|
Toracchio S et al. |
Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11121913
|
You JH et al. |
Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421876
|
Gudjonsson H et al. |
High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9845401
|
De Francesco V et al. |
Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15113366
|
Koivisto TT et al. |
Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15113368
|
Gisbert JP and Calvet X |
Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:22017749
|
Cammarota G et al. |
High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15043520
|
Pellegrini M et al. |
Is a long-term ranitidine-based triple therapy against Helicobacter pylori only a heritage of the past? A prospective, randomized clinicopharmacological study. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:16098001
|
Kawabata H et al. |
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12534411
|
Gomollón F et al. |
Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11012479
|
Wong BC et al. |
Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102962
|
Xiao SD et al. |
High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102963
|
Liu WZ et al. |
Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102964
|
Huang J and Hunt RH |
Clarithromycin-based triple therapies. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102978
|
Osato MS et al. |
Comparative efficacy of new investigational agents against Helicobacter pylori. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11284777
|
Fraser AG |
Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28776748
|
Jung YS et al. |
Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28776746
|
Nista EC et al. |
Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12969089
|
Sheu BS et al. |
Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15691303
|
Wong WM et al. |
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16423001
|
Klok RM et al. |
Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966514
|
Tsuzuki T et al. |
Clarithromycin increases the release of heat shock protein B from Helicobacter pylori. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966545
|
Isomoto H et al. |
High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12848631
|
Gisbert JP et al. |
Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:16268980
|
Ellenrieder V et al. |
Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9701524
|
Miwa H et al. |
Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12823158
|
Lim AG et al. |
Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9218079
|
Zullo A et al. |
Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication? |
2010 |
Aliment. Pharmacol. Ther. |
pmid:20518756
|
Armuzzi A et al. |
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11148433
|
Mégraud F and Lamouliatte H |
Review article: the treatment of refractory Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12786627
|